Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...
Avadel settled with Jazz Pharmaceuticals, clearing legal hurdles for Alkermes' $20/share acquisition. Click to read my update ...
GlobalData on MSN
Alkermes to acquire Avadel for $2.1bn
Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The ...
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
Piper Sandler analyst David Amsellem raised the firm’s price target on Alkermes (ALKS) to $45 from $38 and keeps an Overweight rating on the ...
Harmony Biosciences Holdings, Inc. today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback